MedPath

Vital Signs Camera Study

Not Applicable
Completed
Conditions
Respiration Rate
Heart Rate
Interventions
Device: VSC-MEDlib
Registration Number
NCT06140433
Lead Sponsor
Philips Clinical & Medical Affairs Global
Brief Summary

This study is a single center, prospective clinical investigation which is balanced for gender, age, Body Mass Index (BMI) and skin color. Simultaneous measurements of PR and RR on study participants will be collected in conditions described in IFU and various suboptimal conditions. The study participants will be recorded with the VSC demo app (together with a compatible camera and computing hardware) and reference devices. PR and RR data to be collected by the VSC demo app, will be post-processed after the clinical investigation and compared with the reference devices. Persons who are willing to participate will be asked to provide their consent.

Primary objective:

• To assess the clinical safety and effectiveness of Pulse Rate (PR) and Respiration Rate (RR) measured with the VSC-MEDlib within the intended use compared to the gold-standard reference devices.

Exploratory objective:

• To assess the clinical safety and effectiveness of Pulse Rate and Respiration Rate measured with the VSC-MEDlib during suboptimal circumstances (outside the scope of the intended use), compared to the gold-standard reference devices.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
94
Inclusion Criteria
  • Persons with ASA I or II classification
  • Adult population (age >18 years old)
  • BMI ≥ 18 - ≤ 40 kg/m2
  • Able to intensively exercise for 10 minutes
  • Persons willing to give informed consent
  • Willingness to have vital signs measured by a medical mobile application
  • Willingness to follow study protocol (e.g., put on sunglasses, facial make-up, medical face-mask and sitting still up to 2 minutes)
Exclusion Criteria
  • Vulnerable populations (e.g., age <18 years old, not able to consent by themselves, or immunecompromised or pregnant women)
  • Cardiac arrhythmias (e.g., Atrial Fibrillation, Supraventricular Tachycardia, Ventricular arrhythmia, regular ectopic beats)
  • Persons present signs of infection
  • Participant has known allergic reactions to make-up and/or make-up remover
  • Persons with positive COVID 19 test in last 14 days
  • Participant who exhibit irregular or excessive movement such as tremors, tics, shaking and/or shivering
  • Participant is Philips employee or their family members residing with this Philips employee.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
VSC-MEDlibVSC-MEDlibSaMD: Data collection study. Software to be applied after data collection.
Primary Outcome Measures
NameTimeMethod
Clinical safety and effectiveness VSC-MEDlib according to IFU2 hours

Clinical safety and effectiveness of the non-invasive and contactless measurement of PR by the VSC-MEDlib within the intended use.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Philips

🇳🇱

Eindhoven, Noord-Brabant, Netherlands

© Copyright 2025. All Rights Reserved by MedPath